Rakesh Jhunjhunwala’s all-time favourite gaming stock is in the doldrums. Kalpraj Dharamshi, the veteran value investor, has made out a strong case on why the stock is a great buy at the present valuations. His analysis appears to be in tune with the theory propounded by Howard Marks, the great investment guru
Subscribe to Blog via Email
Join 509 other subscribers
- Raymond Lifestyle has multiple growth drivers. Target Price ₹3000 (+49%)Raymond Lifestyle has multiple growth drivers. It boasts legacy of established brands such as Park Avenue. However brands remain under-penetrated due to sluggish execution in past. Renewed focus on growth could lead to valuation re-rating. TP ₹3000 (+49%) Download research report... Raymond Lifestyle has multiple growth drivers. Target Price ₹3000 (+49%)
- Sunil Singhania's Abakkus has bought 10.69L shares of Aarti Pharma at ₹575 for ₹61.5 CrSunil Singhania's Abakkus has bought 10.69L shares of Aarti Pharma at ₹575 for ₹61.5 Cr. M-Cap is ₹5800 Cr. Promoters hold 46%. Co operates in 3 areas i.e. Xanthine derivatives, API & CDMO/CMO. It is largest Indian manufacturer of Xanthines & has Global market share of 15-20% ... Sunil Singhania's Abakkus has bought 10.69L shares […]
- PNB Housing is undergoing a transformation to morph into a franchise that will be strongerPNB Housing is undergoing a transformation to morph into a franchise that will be stronger, more resilient & with high predictability in earnings trajectory. Risk-reward profile is favorable for a long-term investor. Buy for TP of ₹1160 (38% upside) Download research... PNB Housing is undergoing a transformation to morph into a franchise that will be […]
Recent Posts
- Raymond Lifestyle has multiple growth drivers in place. Buy for target price of ₹3000 (49% upside): Motilal Oswal
- PNB Housing is a strengthening franchise where the risk-reward profile is favorable for a long-term investor. Buy for target price of ₹1160 (38% upside): Motilal Oswal
- Piramal Pharma is seeing strong momentum in CDMO. Buy for target price f ₹320 (27% upside): ICICI Direct
- Hiren Ved has no Banking stocks in his portfolio. Ravi Dharamshi is very bullish about energy transition
- Protean eGov Technologies is a unique play on digital public infrastructure. Buy for target price of ₹2510 (24% upside): ICICI Direct
Recent Comments